DNLI
Price
$14.51
Change
-$0.18 (-1.23%)
Updated
Jul 7, 01:40 PM (EDT)
Capitalization
2.13B
24 days until earnings call
NTRB
Price
$9.11
Change
-$0.80 (-8.07%)
Updated
Jul 7, 11:29 AM (EDT)
Capitalization
110.3M
86 days until earnings call
Interact to see
Advertisement

DNLI vs NTRB

Header iconDNLI vs NTRB Comparison
Open Charts DNLI vs NTRBBanner chart's image
Denali Therapeutics
Price$14.51
Change-$0.18 (-1.23%)
Volume$800
Capitalization2.13B
Nutriband
Price$9.11
Change-$0.80 (-8.07%)
Volume$128
Capitalization110.3M
DNLI vs NTRB Comparison Chart in %
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. NTRB commentary
Jul 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Buy and NTRB is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 07, 2025
Stock price -- (DNLI: $14.69 vs. NTRB: $9.91)
Brand notoriety: DNLI and NTRB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 41% vs. NTRB: 169%
Market capitalization -- DNLI: $2.13B vs. NTRB: $110.3M
DNLI [@Biotechnology] is valued at $2.13B. NTRB’s [@Biotechnology] market capitalization is $110.3M. The market cap for tickers in the [@Biotechnology] industry ranges from $316.35B to $0. The average market capitalization across the [@Biotechnology] industry is $2.39B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileNTRB’s FA Score has 0 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • NTRB’s FA Score: 0 green, 5 red.
According to our system of comparison, NTRB is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 4 TA indicator(s) are bullish while NTRB’s TA Score has 3 bullish TA indicator(s).

  • DNLI’s TA Score: 4 bullish, 5 bearish.
  • NTRB’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, both DNLI and NTRB are a bad buy in the short-term.

Price Growth

DNLI (@Biotechnology) experienced а +1.38% price change this week, while NTRB (@Biotechnology) price change was +26.56% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.38%. For the same industry, the average monthly price growth was +14.03%, and the average quarterly price growth was -0.58%.

Reported Earning Dates

DNLI is expected to report earnings on Jul 31, 2025.

NTRB is expected to report earnings on Oct 01, 2025.

Industries' Descriptions

@Biotechnology (+5.38% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($2.13B) has a higher market cap than NTRB($110M). NTRB YTD gains are higher at: 110.403 vs. DNLI (-27.920). NTRB has higher annual earnings (EBITDA): -9.68M vs. DNLI (-505.16M). DNLI has more cash in the bank: 818M vs. NTRB (2.96M). NTRB has less debt than DNLI: NTRB (282K) vs DNLI (48.6M). NTRB has higher revenues than DNLI: NTRB (2.4M) vs DNLI (0).
DNLINTRBDNLI / NTRB
Capitalization2.13B110M1,940%
EBITDA-505.16M-9.68M5,218%
Gain YTD-27.920110.403-25%
P/E RatioN/AN/A-
Revenue02.4M-
Total Cash818M2.96M27,598%
Total Debt48.6M282K17,234%
FUNDAMENTALS RATINGS
DNLI vs NTRB: Fundamental Ratings
DNLI
NTRB
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
78
Overvalued
PROFIT vs RISK RATING
1..100
10094
SMR RATING
1..100
9498
PRICE GROWTH RATING
1..100
6036
P/E GROWTH RATING
1..100
99100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTRB's Valuation (78) in the null industry is in the same range as DNLI (93) in the Biotechnology industry. This means that NTRB’s stock grew similarly to DNLI’s over the last 12 months.

NTRB's Profit vs Risk Rating (94) in the null industry is in the same range as DNLI (100) in the Biotechnology industry. This means that NTRB’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (94) in the Biotechnology industry is in the same range as NTRB (98) in the null industry. This means that DNLI’s stock grew similarly to NTRB’s over the last 12 months.

NTRB's Price Growth Rating (36) in the null industry is in the same range as DNLI (60) in the Biotechnology industry. This means that NTRB’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's P/E Growth Rating (99) in the Biotechnology industry is in the same range as NTRB (100) in the null industry. This means that DNLI’s stock grew similarly to NTRB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLINTRB
RSI
ODDS (%)
N/A
Bearish Trend 5 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 5 days ago
81%
Bearish Trend 5 days ago
90%
Momentum
ODDS (%)
Bullish Trend 5 days ago
80%
Bullish Trend 5 days ago
84%
MACD
ODDS (%)
Bullish Trend 5 days ago
78%
Bullish Trend 5 days ago
71%
TrendWeek
ODDS (%)
Bullish Trend 5 days ago
78%
Bullish Trend 5 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 5 days ago
75%
Bullish Trend 5 days ago
81%
Advances
ODDS (%)
Bullish Trend 12 days ago
78%
Bullish Trend 6 days ago
81%
Declines
ODDS (%)
Bearish Trend 8 days ago
80%
Bearish Trend 27 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 5 days ago
73%
Bearish Trend 5 days ago
89%
Aroon
ODDS (%)
Bearish Trend 5 days ago
79%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TSNAX18.260.29
+1.61%
Touchstone Sands Capital Select Growth A
LBGAX44.470.60
+1.37%
ClearBridge Mid Cap Growth A
CRFIX12.000.06
+0.50%
Calvert Focused Value I
AFDVX22.330.10
+0.45%
Applied Finance Explorer Investor
PRFDX37.020.15
+0.41%
T. Rowe Price Equity Income

NTRB and

Correlation & Price change

A.I.dvisor tells us that NTRB and SONN have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NTRB and SONN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTRB
1D Price
Change %
NTRB100%
-7.56%
SONN - NTRB
29%
Poorly correlated
-5.54%
RARE - NTRB
27%
Poorly correlated
+1.14%
REPL - NTRB
27%
Poorly correlated
-1.57%
STOK - NTRB
27%
Poorly correlated
-0.61%
DNLI - NTRB
25%
Poorly correlated
-1.41%
More